- Headquarters: Seattle, WA
- Founded: 2006
- phaserx.com
PhaseRx received Nasdaq delisting notice for common stock to be suspended on November 1 absent an appeal -- PhaseRx will appeal
On September 21, 2017, PhaseRx submitted a plan of compliance to Nasdaq addressing how it intended to regain compliance with the continued listing standards by the end of the third quarter of 2017, which was subsequently supplemented on October 10 and 18, 2017. As a result of Nasdaq's rejection of the plan of compliance and initiation of delisting procedures, PhaseRx will proceed to appeal to a Nasdaq Hearing Panel. There can be no assurance that the panel will grant PhaseRx's request for continued listing.
No comments:
Post a Comment